Zevra Therapeutics (ZVRA) Net Cash Flow Growth (1y) (2015 - 2026)
Zevra Therapeutics (ZVRA) Net Cash Flow Growth (1y) (2015 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | NCF Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,132.22 Bn | 67,131.94 Bn | - | -88.82% |
| 2 | Nanobiotix | 1,910.87 Bn | 1,910.81 Bn | - | - |
| 3 | Akari Therapeutics | 989.71 Bn | 989.71 Bn | - | - |
| 4 | BeOne Medicines | 471.60 Bn | 466.80 Bn | 1.35 Bn | 301.06% |
| 5 | Vertex Pharmaceuticals | 121.71 Bn | 114.46 Bn | 2.59 Bn | 453.08% |
| 6 | Regeneron Pharmaceuticals | 69.83 Bn | 61.07 Bn | 3.31 Bn | -125.22% |
| 7 | Belite Bio | 62.74 Bn | 62.74 Bn | - | - |
| 8 | Argenx Se | 55.83 Bn | 50.65 Bn | 1.41 Bn | - |
| 9 | Alnylam Pharmaceuticals | 37.33 Bn | 34.32 Bn | 959.66 Mn | 53.46% |
| 10 | Zevra Therapeutics | 561.87 Mn | 361.25 Mn | 34.32 Mn | 739.22% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 739.22% |
| Dec 31, 2025 | 139.61% |
| Sep 30, 2025 | -56.37% |
| Jun 30, 2025 | 348.57% |
| Mar 31, 2025 | 2,633.55% |
| Dec 31, 2024 | -3,577.50% |
| Sep 30, 2024 | 166.90% |
| Jun 30, 2024 | -114.87% |
| Mar 31, 2024 | 99.39% |
| Dec 31, 2023 | 88.27% |
| Sep 30, 2023 | -242.36% |
| Jun 30, 2023 | 212.16% |
| Mar 31, 2023 | -108.92% |
| Dec 31, 2022 | 74.68% |
| Sep 30, 2022 | -741.79% |
| Jun 30, 2022 | -141.64% |
| Mar 31, 2022 | -116.92% |
| Dec 31, 2021 | -1,593.81% |
| Sep 30, 2021 | 28.13% |
| Jun 30, 2021 | 1,302.17% |